Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release May 26 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Pemetrexed for Injection. This drug is used to treat certain types of cancers, including lung cancer and mesothelioma. The approval allows Zydus to market the drug in various strengths and will be manufactured at Zydus Hospira.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases